CJC-1295 with DAC (Drug Affinity Complex) is a modified version of the peptide CJC-1295. The addition of DAC enhances the stability and half-life of the peptide, allowing it to remain active in the body for a longer duration compared to the standard version. CJC-1295 with DAC functions as an analog of growth hormone-releasing hormone (GHRH) and is designed to stimulate the release of growth hormone (GH) from the pituitary gland.

The DAC modification increases the binding affinity of the peptide to plasma proteins, which supports a sustained release in the body. It is important to note that CJC-1295 with DAC has not received FDA approval for human use, and its safety and efficacy have not been established in clinical trials.

Offered in a sterile, sealed vial as a lyophilized powder, this product is manufactured to exceed 99% purity, with rigorous testing by HPLC and LC-MS to confirm quality and consistency. Designed exclusively for laboratory research and development, it ensures stability and reliability for advanced scientific studies.Peptides and peptide blends are available for purchase online. The products featured on this website are not classified as medicines or drugs and have not received FDA approval for the prevention, treatment, or cure of any medical condition, ailment, or disease. All articles and product information provided here are intended solely for informational and educational purposes. Additionally, these products are offered exclusively for in vitro research. Bodily introduction of any kind into humans or animals is strictly forbidden by law. These products are offered as research chemicals only.